SLE patients (n=116) | |
Disease duration (years)* | 5.2 (0.1–28) |
BILAG score* | 13.0 (0–48) |
SLEDAI score* | 10.5 (0–39) |
Organ involvement | |
n | 100 |
Serositis | 23 |
NPSLE | 61 |
LN (proliferative LN) | 68 (39) |
Treatment with prednisolone (or equivalent) | |
n | 102 |
Dose (mg/day)* | 40 (5–80) |
No of patients on combination therapy at enrolment | |
Cyclophosphamide | 40 |
Azathioprine | 6 |
Ciclosporin | 7 |
Tacrolimus | 1 |
Mizoribin | 2 |
Disease activity and clinical response to corticosteroids | |
Inactive disease | 10 |
Responders | 55 |
Low responders | 51 |
Organ involvement in low responders | |
n | 49 |
Serositis | 12 |
NPSLE | 37 |
LN (proliferative LN) | 38 (23) |
↵*Data are median (range).
BILAG, British Isles Lupus Assessment Group 2004 Index; LN, lupus nephritis; NPSLE, neuropsychiatric systemic lupus erythematosus; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.